Free Trial
CVE:DMT

Small Pharma (DMT) Stock Price, News & Analysis

Small Pharma logo
C$0.15 -0.01 (-6.25%)
As of 10/20/2023

About Small Pharma Stock (CVE:DMT)

Key Stats

Today's Range
C$0.15
C$0.16
50-Day Range
C$0.15
C$0.15
52-Week Range
C$0.06
C$0.22
Volume
1.89 million shs
Average Volume
296,159 shs
Market Capitalization
C$50.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.

Receive DMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter.

DMT Stock News Headlines

Small Pharma (CVE:DMT) Trading Down 6.3% - Here's Why
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Milestone Pharmaceuticals Prepares for CARDAMYST Approval
LTR Pharma’s SPONTAN Nasal Spray Poised for Global Impact
See More Headlines

DMT Stock Analysis - Frequently Asked Questions

Small Pharma's stock was trading at C$0.15 at the beginning of 2025. Since then, DMT shares have increased by 0.0% and is now trading at C$0.15.
View the best growth stocks for 2025 here
.

Shares of DMT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Small Pharma investors own include Bombardier, Inc. Class B (BBD.B), Arrival (ARVL), Air Canada (AC), Beyond Meat (BYND), BioSig Technologies (BSGM), Aveanna Healthcare (AVAH) and Actinium Pharmaceuticals (ATNM).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:DMT
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-19,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$-1,162.00
Price / Sales
-43,343.80
Cash Flow
C$0.13 per share
Price / Cash Flow
1.13
Book Value
C$0.03 per share
Price / Book
5.00

Miscellaneous

Free Float
N/A
Market Cap
C$50.37 million
Optionable
Not Optionable
Beta
0.86
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (CVE:DMT) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners